Filing Flows › Comparisons › SEPN vs XLO
Septerna vs Xilio Therapeutics: SEPN and XLO compared
Septerna is the larger company: $18.9M of revenue in its latest quarter (Q3 2026) against $18.7M for Xilio Therapeutics (Q2 2026). Xilio Therapeutics is growing faster (+131% against -12% a year earlier). Xilio Therapeutics is more profitable, with an operating margin of -18.7% against -144.2%.
Where the money goes: SEPN and XLO
Septerna (SEPN) · Q3 2026
Septerna, Q3 2026: revenue $18.9M (-12% year over year), operating margin -144.2%, net loss $26.6M, operating cash flow −$13.8M. The chart follows the revenue to costs, profit and cash.
Xilio Therapeutics (XLO) · Q2 2026
Xilio Therapeutics, Q2 2026: revenue $18.7M (+131% year over year), operating margin -18.7%, net loss $6.4M, operating cash flow −$18.8M. The chart follows the revenue to costs, profit and cash.
| Septerna (SEPN) | Xilio Therapeutics (XLO) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $18.9M | $18.7M |
| Revenue growth, Y/Y | -12% | +131% |
| Operating margin | -144.2% | -18.7% |
| Net earnings | −$26.6M | −$6.4M |
| Net margin | -140.8% | -34.1% |
| Operating cash flow | −$13.8M | −$18.8M |
Questions
Which is bigger, Septerna or Xilio Therapeutics?
Septerna is the larger company: $18.9M of revenue in its latest quarter (Q3 2026) against $18.7M for Xilio Therapeutics (Q2 2026).
Is Septerna or Xilio Therapeutics growing faster?
Xilio Therapeutics is growing faster (+131% against -12% a year earlier).
Which is more profitable, Septerna or Xilio Therapeutics?
Xilio Therapeutics is more profitable, with an operating margin of -18.7% against -144.2%.
More: Septerna earnings · how Septerna makes money · Xilio Therapeutics earnings · how Xilio Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 9, 2026; 10-Q filed Aug 12, 2026). Fiscal quarters can end on different dates. Not investment advice.